AstraZeneca's obesity case rests on two readouts due this fall

AstraZeneca is trying to build a case that it belongs among the leaders in obesity drug development, but its most important evidence is still to come. The company is expected to present data on its amylin analog AZD6234 at the European Association for the Study of Diabetes meeting, running September 28 to October 2 in Italy, while its oral GLP-1 pill elecoglipron has moved into Phase 3 testing for obesity and type 2 diabetes, with analysts at William Blair placing readouts in 2027 or 2028 ^[1].

AZD6234 is described as a selective amylin receptor peptide agonist, a drug class distinct from the GLP-1 medicines that dominate the market today, such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) ^[1]. Detailed Phase 2 numbers for AZD6234 have not yet been published ^[1]. Beyond the EASD presentation, William Blair expects two more readouts this fall: results from a Phase 2 study of AZD6234 in people with overweight or obesity and type 2 diabetes who are already on stable background GLP-1 therapy, and results from the Phase 2b ASCEND study, which tests AZD6234 combined with AZD9550, a GLP-1/glucagon dual agonist, in people with obesity ^[1].

On the oral pill side, AstraZeneca CEO Pascal Soriot told investors in February that elecoglipron has "a very competitive profile," and pointed to the company's decision to advance the drug into Phase 3 as a sign of confidence in it ^[1]. A separate late-stage study is testing elecoglipron in type 2 diabetes alone ^[1]. AstraZeneca's broader pipeline is large: as of late July 2026, the company listed 183 projects in development, including 21 new molecular entities in late-stage testing, though most of that pipeline is in cancer and other disease areas, not obesity ^[2].

The stakes are shaped by how far ahead the market leaders already are. Eli Lilly's tirzepatide franchise, sold as Mounjaro and Zepbound, has been setting sales records, and its oral pill Foundayo is expanding into more than 40 markets ^[1]. Novo Nordisk's oral Wegovy pill held roughly 90% of weekly oral GLP-1 prescriptions as of July, covering about 1.5 million people, even after a revenue stumble in the second quarter ^[1]. Roche is also pushing ahead, with a dual GLP-1/GIP drug called enicepatide that produced 22.5% weight loss in a separate Phase 2 study, and a Pharma Day presentation planned for September 28 ^[1]. Against that backdrop, AstraZeneca is still working to generate the data that would justify a place in the conversation.

Why it matters for patients

None of AstraZeneca's obesity candidates are approved or available to patients today, and the readouts due this fall are early- and mid-stage results, not final proof that the drugs work or are safe for long-term use. For people currently using semaglutide or tirzepatide products, this news does not change anything about current prescriptions, coverage, or side effects. What it does signal is that a different drug mechanism, amylin analogs like AZD6234, potentially combined with GLP-1 or glucagon-targeting drugs, is moving through testing and could eventually offer another option, including for people already on an incretin therapy ^[1]. Whether that pans out depends on data that has not yet been made public.

What happens next

AZD6234 data are expected at the EASD meeting in Italy between September 28 and October 2, 2026, alongside Phase 2 results in patients on background GLP-1 therapy and from the Phase 2b ASCEND study of AZD6234 with AZD9550 ^[1]. Phase 3 readouts for the oral pill elecoglipron in obesity and type 2 diabetes are not expected until 2027 or 2028, according to analyst estimates ^[1].